BEAM JPM 2025 Presenation_vF.pdf

1、PRECISION GENETIC MEDICINES THROUGH BASE EDITING2025 J.P.Morgan Healthcare ConferenceNASDAQ:BEAMCautionary note regarding forward-looking statementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking st

2、atements include statements regarding:the initiation,timing,progress and results of preclinical studies and research and development programs,including the initiation,design and progress of clinical trials,including trials for BEAM-101,BEAM-103,BEAM-301 and BEAM-302;the advancement of our pipeline a

3、nd additional liver programs in multiple preclinical studies;our current expectations and anticipated results of operations,including our expected use of capital;our estimated cash,cash equivalents and marketable securities as of December 31,2024 and our expectations related thereto;the sufficiency

4、of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available;and the therapeutic applications and potential of our technology,including our potential to develop life-long,curative,precision genetic medici

5、nes for patients through base editing,including potential safety advantages,all of which are subject to known and unknown important risks,uncertainties and other factors that may cause our actual results,performance or achievements,market trends,or industry results to differ materially from those ex

6、pressed or implied by such forward-looking statements.Therefore,any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such.Without limiting the foregoing,the words anticipate,expect,suggest,plan,vision,“strategy,”“poss